AB0124 explained

Image Class:skin-invert-image
Class:Serotonin 5-HT2A receptor positive allosteric modulator
Pubchem:167475110
Synonyms:AB-0124; ABO124; ABO-124
Iupac Name:N-[2-(dimethylamino)ethyl]-4-(2-phenylethyl)piperidine-2-carboxamide
C:18
H:29
N:3
O:1
Smiles:CN(C)CCNC(=O)C1CC(CCN1)CCC2=CC=CC=C2
Stdinchi:1S/C18H29N3O/c1-21(2)13-12-20-18(22)17-14-16(10-11-19-17)9-8-15-6-4-3-5-7-15/h3-7,16-17,19H,8-14H2,1-2H3,(H,20,22)
Stdinchikey:YAFSEZSVGMQXTE-UHFFFAOYSA-N

AB0124 is a serotonin 5-HT2A receptor positive allosteric modulator.[1] [2]

Notes and References

  1. Merritt RF, Anastasio N, Zhou J, Cunningham K . ACNP 64th Annual Meeting: Poster Abstracts P292-583 . Neuropsychopharmacology . 51 . Suppl 1 . 243–409 . January 2026 . 41507445 . 12783661 . 10.1038/s41386-025-02280-3 . January 1, 2027 .
  2. WO . 2023/023287A1 . Novel heterocyclic compounds as serotonin (5-ht) 5-ht2a and 5-ht2c receptor positive allosteric modulators . Zhou J, Cunningham KA, Bolinger AA, Anastasio NC . University of Texas System, University of Texas at Austin . 23 February 2023 .
  3. Bolinger AA, Zamora J, Merritt CR, Anastasio NC, Cunningham KA, Zhou J . Discovery of novel serotonin 5-HT2A receptor positive allosteric modulators . March 2024 . 16TH Annual Behavior, Biology, and Chemistry: Translational Research in Substance Use Disorders, San Antonio, Texas | Embassy Landmark | 22-24 March 2024 | url = https://ww2.uthscsa.edu/ARTT/BBC/print/2024Program.pdf | quote = Synthesizing and screening novel small molecules, we identified potent positive allosteric modulators (PAMs) of 5-HT2AR. Further analysis and comparison against CNS receptors, channels, and transporters led to the identification of AB0124 a potential candidate with high specificity. This compound has demonstrated functional increases in 5-HT-induced Ca2+ release at the micromolar level for the 5-HT2AR over other serotonin receptors. With promising in vitro pharmacological and physicochemical profiles, our novel 5-HT2AR PAMs hold potential as neurotherapeutics for [cocaine use disorder (CUD)]. }}[2] It is highly selective for potentiation of the serotonin 5-HT2A receptor, with no potentiation of the serotonin 5-HT2B and 5-HT2C receptors. In addition, it showed no orthosteric agonistic activity at any of the serotonin 5-HT2 receptors. AB0124 has been studied in combination with the serotonin 5-HT2 receptor agonist (R)-DOI in animal models of cocaine use disorder. The chemical synthesis of AB0124 has been described. The drug was patented in 2022 and was first described in the scientific literature by 2024.

    See also

    References

    .